Albert Einstein University of Medication receives SU2C grant for cancer research Matthew Levy.

This represents an exciting new avenue of study at Einstein directed to the advancement of therapies that specifically target tumor cells. This award to Dr. Levy is an extremely appropriate honor for his novel research applying chemical biology approaches to cancer complications, stated Vern Schramm, Ph.D., the Ruth Merns Chair in Biochemistry, who recruited Levy to join Einstein’s faculty in 2007. His study typifies the integration of fresh systems across disciplines to possess effect on fundamental chemistry principles and also in human disease. In receiving the SU2C grant, Dr. Levy joins 12 experts from seven other institutions including Dana-Farber Cancer Institute, Children’s Medical center Boston, and Fred Hutchinson Cancers Study Institute.A complete list of the members of the steering committee and the specialized working group is provided in the Supplementary Appendix, available with the entire text of this article at NEJM.org. Study Populace, Sampling, and Eligibility Criteria We recruited a convenience sample of 100 man survivors from the Western Region District of Sierra Leone, which include the capital of Freetown. We recognized study individuals who, at informational events that were held in conjunction with survivor associations, indicated curiosity in participation, in addition to persons who were referred from Ebola treatment centers.